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Abstract
Hypoxia-inducible factor (HIF) functions as a master transcriptional regulator for adaptation to hypoxia by inducing adaptive
changes in gene expression for regulation of proliferation, angiogenesis, apoptosis and energy metabolism. Cancers with
high expression of the alpha subunit of HIF (HIFa) are often malignant and treatment-resistant. Therefore, the development
of a molecular probe that can detect HIF activity has great potential value for monitoring tumor hypoxia. HIF prolyl
hydroxylases (HPHDs) act as oxygen sensors that regulate the fate of HIFa protein through its oxygen-dependent
degradation (ODD) domain. We constructed a recombinant protein PTD-ODD-HaloTag (POH) that is under the same ODD
regulation as HIFa and contains protein transduction domain (PTD) and an interchangeable labeling system. Administration
of near-infrared fluorescently labeled POH (POH-N) to mouse models of cancers allowed successful monitoring of HIF-active
regions. Immunohistochemical analysis for intratumoral localization of POH probe revealed its specificity to HIF-active cells.
Furthermore, lack of the PTD domain or a point mutation in the ODD domain abrogated the specificity of POH-N to HIF-
active cells. Overall results indicate that POH is a practical probe specific to HIF-active cell in cancers and suggest its large
potential for imaging and targeting of HIF-related diseases.
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Introduction
Hypoxia-inducible factor (HIF) is critical for cellular adaptation
in response to limited oxygen availability and regulate a wide array
of genes in response to activation by cellular oxygen-sensing
mechanisms. In cancers, hypoxia and genetic alterations in
oncogenes and tumor suppressor genes increase HIF activity [1].
Many induced by HIF are critically involved in aspects of cancer
biology, including immortalization, maintenance of stem cell
pools, cellular differentiation, genetic instability, vascularization,
metabolic reprogramming, autocrine growth factor signaling,
invasion/metastasis and resistance to treatment [2,3]. Therefore,
early detection of HIF-active regions is important to initiate timely
and appropriate treatments for malignant cancers.
HIF is a heterodimer of bHLH-PAS proteins. It consists of an
alpha subunit (such as HIF-1a), with suppressed degradation
during hypoxic conditions, and ubiquitously expressed beta
subunits (such as HIF-1b) [1]. Under well-oxygenated conditions,
HIFa is hydroxylated by members of the prolyl hydroxylase
domain (PHD) family, which target highly conserved prolyl
residues located in the oxygen-dependent degradation (ODD)
domain [4,5]. Trans-4-prolyl-hydroxylation of HIFa enables its
recognition by the von Hippel-Lindau tumor suppressor protein
(pVHL), a component of ubiquitin ligase complexes [6]. HIFa is
then polyubiquitinated and undergoes proteasomal degradation
when oxygen is available [6]. Hypoxia suppresses the rate of HIF
hydroxylation, allowing HIFa to accumulate.
We previously reported that a fusion protein containing
ODD548–603 of human HIF-1a is efficiently degraded under
normoxic conditions through a pVHL-mediated protein degrada-
tion system as HIF-1a [7] and that a fusion protein PTD-
ODD548–603-procaspase-3 significantly increased caspase-3 activity
and selectively induced apoptosis in HIF-active/hypoxic cancer
cells in vitro and in vivo [7-12]. The protein transduction domain
(PTD) transports the fused proteins into cells and allows them to
spread throughout the body by passive diffusion [13,14].
In the present study, we constructed PTD3-ODD-HaloTag
(POH), which is easily labeled with any chemical at a specific site
through HaloTag, an interchangeable labeling system [15]. We
labeled HaloTag with near-infrared fluorescence (NIRF) dyes and
injected the resultant PTD3-ODD-HaloTag-ligand-NIRF dye
(POH-N) into model mice with cancers, resulting in successful
monitoring HIF-1-active [HIF (+)] regions in the model mice.
Overall results demonstrate the specificity of PTD3-ODD fusion
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15736proteins to HIF (+) cells and their large potential for imaging and
targeting of HIF-related diseases.
Results
Construction of a near-infrared fluorescently labeled
imaging probe
The recombinant PTD-ODD-HaloTag (POH) fusion protein
was constructed to specifically image and target HIF (+) regions.
Although PTD-ODD fusion proteins have been shown in vivo to be
efficiently delivered to and specifically located in hypoxic regions
of the tumors by the function of the PTD and ODD domains,
respectively, PTD-ODD fusion proteins with different functions
have to be prepared separately. The HaloTag domain endows
POH with any function via an interchangeable labeling system,
enabling easy preparation of POH with different functions. In this
study, POH was fluorescently labeled by the HaloTag inter-
changeable labeling system and examined for possible application
as an in vivo imaging probe specific to HIF (+) regions. POH was
labeled by covalent binding of near-infrared fluorescent (NIRF)
dye-conjugated HaloTag-ligand (HL-N) to a specific site in the
HaloTag domain [15] so that the NIRF labeling would not affect
the function of the PTD and ODD domains (Figure 1A). For the
NIRF dyes, we used two NIRF dyes, IR800 [16] and Alexa Fluor
750. Both have excitation and emission wavelengths in 700–
800 nm where non-specific background fluorescence is consider-
ably reduced [17]. The labeling efficiency of POH with HL-IR800
(HL-I) or HL-Alexa Fluor 750 (HL-A) was .0.7 and the final
products POH-N [POH-I (PTD-ODD-HL-IR800) and POH-A
(PTD-ODD-HL-Alexa Fluor 750)] were stable and did not
contain any obvious side products (Figure 1B). The expected
process for POH-N to image HIF (+) cells are shown in Figure 1C
and required functions for POH-N are as follows: 1) efficient
penetration across the cell membrane by the PTD function; 2)
rapid degradation of POH by the ODD function in HIF-inactive
[HIF (-)] cells; and 3) rapid diffusion of NIRF molecules from
HIF(-) cells. We verified the each process with POH-I and POH-
A. Rapid diffusion of NIRF molecules from HIF (-) cells was
observed with both POH-N probes (Figure 1D).
PTD in POH-N enables efficient entry into cells and in vivo
delivery
First, efficient penetration across the cell membrane by the PTD
function was examined by using POH-I. The POH fusion protein
contained PTD3 polypeptide, which has more efficient membrane
penetrating activity than known PTD polypeptides in a PTD-
ODD fusion protein (Figure S1). To examine the function of
PTD3, POH-I without PTD3 (OH-I) was constructed (Figure 1B)
and SUIT-2/HRE-Luc cells were treated with OH-I or POH-I.
POH-I entered cells much more efficiently than OH-I (Figure 2A),
confirming that efficient penetration of the cell membrane is
dependent on PTD function [14]. To analyze PTD function in
vivo, POH-I and OH-I were intravenously injected into mice
carrying subcutaneous xenografts of SUIT-2/HRE-Luc cells.
Although OH-I and POH-I were delivered to the tumors, the
amount and retention time of OH-I in tumors was much less than
those of POH-I (Figure 2B). The ratio of the target (fluorescent
intensity of tumors) versus background (fluorescent intensity of
muscles in the hind legs) (T/B ratio) of POH-I was high (.2.0) 15–
24 h after POH-I administration, while the T/B ratio of OH-I was
less than 1.5 throughout the observation period (Figure 2C).
Similar results were obtained by using POH-A. These results
indicate that PTD in POH-N contributes to its efficient entry into
tumor cells, and therefore, contributes to the tumor-specific
imaging of POH-N.
The specificity of POH-N to HIF (+) cells is dependent on
ODD function
When the cells were treated with POH-I, significantly higher
levels of POH protein and NIRF signal were detected in cells
cultured in hypoxia (1% O2) and in cells treated with CoCl2,a
PHD inhibitor, compared with normoxic (21% O2) cells
(Figures 3A and 3B). Similar results were obtained in experiments
using other human cancer cell lines (Figure S2). Moreover, when
PHD2 expression was significantly suppressed in PHD2-KD
subclones by using shRNA (Figure 3C), there were significantly
reduced levels of POH-I signal in normoxia than in hypoxia in
control SUIT-2/HRE-Luc cells but not in PHD2-KD subclones
(Figure 3D). These results indicate that the rapid degradation of
POH in HIF (-) cells is regulated by PHD2, which modifies the
ODD domain of HIFa under normoxic conditions [18].
When POH-I was injected into mice carrying subcutaneous
xenografts of SUIT-2/HRE-Luc cells via the tail vein, fluorescence
signals were detected throughout the body of the mice within a few
minutes and gradually became weaker(Figure 2B). Accumulationof
POH-I in tumors was detected as soon as 6 h after injection
(Figure 2B). SUIT-2/HRE-Luc cells stably carry 5HRE-luciferase,
a luciferase reporter gene under the control of the HIF-1-dependent
promoter, and thus HIF-1-activity in xenografts [HIF (+) regions]
can be noninvasively monitored by bioluminescence imaging [12].
Most POH-I was cleared from the mice and tumor-specific images
were obtained by 24 h after POH-I administration, resulting in a
high T/B ratio (.2.0) in most of the tumors (Figure 3E). A good
correlation (R=0.7767) was observed between bioluminescence
intensity of the tumors and the T/B ratio of the POH-I probe
(Figure 3E). Ex vivo imaging of tumors at 24 h after POH-I injection
revealed thatmostfluorescent imagesofPOH-Ioverlappedwith the
bioluminescence images, which indicated HIF (+) regions
(Figure 3F). A relatively high level of fluorescence was also observed
in some clearance-related organs (Figure S3).
A point mutation in the ODD domain abrogates the
specificity of POH to HIF (+) cells
The contribution of the ODD domain in POH to its HIF (+)c e l l -
specificity was further examined in vitro and in vivo using POmH-I,
whichhad a point mutation corresponding to human HIF-1a(P564G)
in the ODD domain and thus lacked ODD regulation [19]. The
relative fluorescent intensity and fusion protein retained in cells treated
with POmH-I were significantly higher than in cells treated with
POH-I under normoxic conditions (Figure 4A), indicating that ODD
contributed to the rapid diffusion of fluorescence from HIF (-) cells.
When POH-I and POmH-I were injected into mice via the tail vein,
the clearance of POH-I was significantly faster than that of POmH-I
in mice without any tumors (Figures 4B and 4C), suggesting that
ODD of POH accelerates its clearance from normal tissues. When
POmH-I was injected into tumor-bearing mice, tumors were imaged
(Figure 4D) and the clearance of POmH-I was significantly slower
than that of POH-I. A greater amount of POmH-I was retained in the
muscles as well as in the tumors than POH-I throughout the
observation period (Figure 4E). These data indicate that ODD
contributes to the rapid clearance of POH-I from HIF (-) cells.
Immunohistochemical analysis reveals the specificity of
POH probe to HIF (+) cells in tumors
To examine the specificity of the POH probe to HIF (+) cells,
we examined the intratumoral localization of POH in more detail.
Optical Imaging of HIF-Activity In Vivo
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the fluorescent signals had significantly decreased throughout the
body of the mice (Figure 2B). In tumor sections, pimonidazole-
positive severe hypoxic (pO2 ,10 mmHg) [20] regions were
located adjacent to the necrotic regions and generally did not
overlap with HIF-1a, as previously described [21]. Both HIF-1a
and POH were detected in regions closer to blood vessels than
regions positive for pimonidazole, and mostly overlapped
(Figure 5A). Conversely, POmH was widely distributed around
the blood vessels (Figure 5A). These results confirmed that POH
was efficiently delivered to and was located in HIF (+) regions in
tumors. In tumor cells, HIF-1a was located in cell nuclei, while
POH was predominantly located in the cytoplasm (Figure 5B),
consistent with the fact that POH lacks the C-terminal nuclear
localization signal of HIFa, which is important for HIF nuclear
translocation [22]. Overall, these results demonstrate the specific-
ity of POH to HIF (+) cells.
In vivo imaging of HIF-1-active cancer cells in an
orthotopic pancreatic cancer model
Next, we examined if POH-N was able to detect small localized
and metastasized tumors in an orthotopic pancreatic cancer
model, in which HIF (+) cancer cells play a central role in
pancreatic cancers during local invasion and metastasis [12].
Fluorescent images corresponding to the images of bioluminescent
signals, indicating HIF (+) cancer cells, were obtained at 9–24 h
Figure 1. Preparation of POH-N probes. (A) Structure of the POH-N probes. POH fusion protein is composed of PTD, ODD and HaloTag domains.
HaloTag ligand labeled with NIRF dye (HL-N) is covalently bound to POH via HaloTag domain to form POH-N probe. (B) SDS-PAGE of prepared probes.
PTD-ODD-HaloTag (POH), POmH (POH with a point mutation in the ODD domain) and ODD-HaloTag (OH) fusion proteins were mixed with Alexa
Fluor 750- or IR800-labeled HaloTag ligand (HL-A or HL-I) and then unbound HL-A or HL-I was removed by column purification. Probes resolved by
SDS-PAGE were stained with Coomassie Blue (upper panel). Fluorescence was scanned by IVIS using excitation (Ex) and emission (Em) filters indicated
below the gels (bottom panel). (C) Mechanism of selective imaging for HIF (+) cells. In cells without HIFa (HIF (–) cells), POH-N is immediately
degraded through HPHD-mediated ODD and the resultant POH-N fragments and HL-N are diffused from the cells. In cells with HIFa [HIF (+) cells],
POH-N is more stable and a clear contrast between cells with versus without HIF activity can be achieved. (D) POH-A and POH-I were added to the
culture medium of SUIT2/HRE-Luc cells. After incubation for 1 h under normoxic conditions, the cells were washed and fluorescence intensity was
measured (uptake). The cells were further cultured under normoxic conditions for 30 min and fluorescence intensity was measured again (residual).
*P,0.01.
doi:10.1371/journal.pone.0015736.g001
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successfully detected a small tumor localized in the pancreas
(Figure 6B). Small metastasized pancreatic cancers in the
peritoneum and stomach were also detected by POH-A
(Figure 6C). We also evaluated intravenous injection of POH-N,
but this proved unsuccessful because the tumor was not effectively
labeled (Figure S4). No fluorescent signal was detected in the
abdominal organs of mice or HIF (+) cancer with bioluminescent
signals (Figure S5), indicating that neither autofluorescence nor
bioluminescence influenced specific image acquisition. Fluorescent
3D images corresponding to 3D images of bioluminescent signals
further confirmed the specificity of the POH probe to the HIF (+)
pancreatic cancers (Figure 6D). We also successfully monitored the
progression of pancreatic cancer by repeated injections of POH-I
in the same mice (Figure 6E). Taken together, these results
indicate that POH is a practical probe to detect HIF (+) cancers in
orthotopic cancer models as well as subcutaneous cancer models.
Discussion
We report, for the first time to our knowledge, non-invasive
fluorescent monitoring of HIF-active microenvironments in cancer
in living animals using a oxygen-dependent degradation protein
probe, POH. Many hypoxia-specific probes have been reported,




64Cu-ATSM [25]. These label
hypoxic regions with reductase activity and have been used to
image hypoxic tissues in tumors, mice and humans. In contrast,
POH is more specific for HIF (+) regions, which are closely
associated with the relatively mild hypoxic status of cells and do
not overlap with regions labeled by pimonidazole (Figure 5 and
ref. [21]), a nitroimidazole compound similar to FMISO, that
targets reductases to detect severely hypoxic regions
(pO2#10 mmHg) [20]. Furthermore, in cancers, HIF activity
does not always reflect intratumoral hypoxic status. HIFa
expression is increased by genetic changes in the components of
the PI3K-mTOR growth signal pathways, in oncogenes products
such as ras and raf or in the von Hippel-Lindau and p53 tumor
suppressor proteins [1,3,26–29]. Therefore, there is an urgent
need for an imaging probe to detecting HIF (+) cells. Many
luciferase reporter genes, which specifically image HIF (+) cells,
have been developed [30–32]. However, the use of luciferase
reporter genes is limited because endogenous expression of the
reporter genes in target cells is required. The current study is the
first to demonstrate an exogenous optical probe specific to HIF (+)
cells. We present three prerequisites for an optical HIF (+)-specific
Figure 2. In vivo optical imaging of HIF-1 activity in subcutaneous cancers with POH probe and its PTD function in vitro and in vivo.
(A) Membrane permeability of POH-I and OH-I in SUIT-2/HRE-Luc cells. The cells cultured under normoxic or hypoxic conditions were co-cultured with
POH-I or OH-I for 1 h and then the fluorescent intensity of cell lysates was measured. The experiments were repeated three times. (B) Representative
in vivo image after 2 nmol of POH-I or OH-I administration. Nude mice carrying SUIT-2/HRE-Luc xenografts in both forefeet were imaged at the
indicated times after probe injection. The right panel (HIF-1) shows bioluminescence images at 24 h. The bottom panels were magnified images of
tumor area of middle panels. (C) The relative fluorescence intensity of the tumor to muscle (T/B ratio). Fluorescence intensities of the SUIT-2/HRE-Luc
xenografts and the muscle of the hind foot were measured at the indicated times after POH-I administration. *P,0.01, n=5.
doi:10.1371/journal.pone.0015736.g002
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N fits these criteria (Figures 1, 2, 3, 4, 5).
Whole-body imaging using bioluminescence and fluorescence can
greatly refine our understanding of small animal models of human
physiology and disease [17,33,34]. We took advantage of the multiple
optical imaging techniques and evaluated the target specificity of
fluorescently labeled POH by using HIF-specific bioluminescence
imaging in cancer mouse models (Figures 2, 3, 4, 6).
We failed to detect pancreatic cancer after intravenous injection
of POH-N probes (Figure S4), possibly due to preferential uptake
of the probe by the liver before reaching the pancreas. However, it
is also possible that the pancreas showed poor uptake of the probes
or less blood flow to the xenografts.
In our experiments, OH-I was delivered to the tumors in
detectable amounts and imaged tumors (Figure 2B) probably due
to high blood supply to tumors [35]. However, its retention time
was significantly shorter than POH-I and it did not give clear
images of the tumors (Figure 2B), indicating that PTD increases
the retention of POH-I by transducing it into tumor cells. POH-I
was also delivered to regions with less blood flow, including the
hypoxic regions of tumors (Figure 5A), most probably by diffusion.
These results further support the idea that PTD allows PTD-ODD
fusion proteins to be delivered to regions far from blood vessels in
tumors and support previous studies in which hypoxic/HIF (+)
cancer cells were eradicated by PTD-ODD-procaspase-3 [7–12].
POH-N was successfully detect ischemic lesions in mouse models
for ischemic diseases such as focal cerebral ischemia (Fujita et al. in
preparation) and myocardial infarction (Watanabe et al. in prepara-
tion), suggesting thatPOH could beused todeliver any drugselectively
to hypoxic tissue, including the penumbra, which has potential for
recovery, and therefore, is a target for medical interventions.
POHwassignificantlyaccumulatedintumors(Figure2B),andhad
been specifically detected in HIF (+) cells (Figure 5) 3–6 h after
administration, although some strong fluorescent signals were also
detected in clearance organs, especially in the bladder; this is also
observed in clinical PET imaging such as
18F-Fluorodeoxyglucose-
PET. Currently, clinical application of optical imaging probes is
limited to endoscopic and intraoperative uses, and thus clinical
applicationofPOH-Nwould belimited.However,POH-Nwouldbe
a useful tool for translational studies using small animals. Moreover,
as the HaloTag ligand can be conjugated to a wide range of
biomaterials, including radioisotopes and anti-apoptotic agents
through an interchangeable labeling system, POH offers sensitive
imaging and targeting bioprobes with specificity for HIF (+) cells;
POH can be used in a wide range of applications, including as
imaging probes for PET, single photon emission computed
tomography and MRI, to deliver drugs for treatment of cancer and
ischemic diseases, and to analyze the biology of HIF. Further studies
are needed to evaluate the tissue specificity and pharmacokinetic
characteristics of POH to determine its most appropriate clinical uses,
aswell as identifythe most appropriatesites of administrationto avoid
unwanted accumulation or rapidexcretion, based on the target tissue.
Materials and Methods
Ethics statement
All animal experiments were performed with the approval of the
Animal Experiment Committees of Kyoto University Graduate
School of Medicine and conducted according to relevant national
and international guidelines.
Mice
Male Balb/c nu/nu were purchased from Oriental Yeast Co.,
Ltd. All mice underwent experiments at 6–10 weeks of age.
Cells and culture conditions
In SUIT-2/HRE-Luc cells, HIF-1a stability is strictly regulated
by oxygen concentration (HIF-1a expression is undetectable under
Figure 3. Characterization of POH probe in vitro and in vivo. (A
and B) Correlation of POH stability and the expression of HIF-1a. The
SUIT-2/HRE-Luc cells (1.5610
5) cultured under normoxic (N) or hypoxic
(H) conditions with 250 mM CoCl2 (Co), a HPHD inhibitor, were treated
with POH protein and analyzed by western blotting (representative blot
is shown) (A) and measurement of fluorescent intensity (B) with an Ex/
Em wavelength of 710 nm/800 nm (P,0.05, n=3). Representative
fluorescence images are shown below the graphs. (C and D) PHD2
regulation of POH stability. The three independent SUIT-2/HRE-Luc/
PHD2-KD cell lines (KD1, KD2 and KD3) with reduced PHD2 protein
expression (C), which were isolated after stable transfection of a PHD2-
specific shRNA plasmid into SUIT-2/HRE-Luc cells, were cultured under
normoxic (N) or hypoxic (H) conditions and were treated with POH-I for
1 h. The cells were cultured in fresh medium and the probes remained
in the cells was estimated by the measurement of fluorescent intensity
of cell lysates. The experiments were repeated three times and a relative
value (hypoxia =1) means 6 SEM are shown (D). *P,0.05 (vs. normoxic
condition). (E) Correlation between tumor bioluminescence intensity
and the T/B ratio (relative fluorescence intensity of the tumors to the
muscle). Bioluminescence and fluorescent intensities of xenografts were
measured 24 h after POH-I administration. Bioluminescence intensity
and T/B ratio show the coefficient value of 0.7767. n=29. (F)
Representative ex vivo bioluminescence (HIF-1) and fluorescence
(POH-I) images of excised subcutaneous tumors. Nude mice carrying
SUIT-2/HRE-Luc xenografts in both forefeet were injected with POH-I
and dissected 24 h after probe administration. Bar =10 mm.
doi:10.1371/journal.pone.0015736.g003
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conditions [12]. SUIT2/HRE-Luc/PHD2-KD cells were cloned
after transfection with a pRS shRNA vector encoding a 29 mer
shRNA specific for PHD2 (Origene, Rockville, MD, USA) into
SUIT2/HRE-Luc cells. Luciferase-expressing subclones under
normoxic conditions were selected. All the cells were maintained
at 37uC in 5% FCS-Dulbecco’s-modified Eagle’s medium (Nacalai
Tesque, Kyoto, Japan) supplemented with penicillin (100 units/
ml) and streptomycin (100 mg/ml). Hypoxic cell cultures were
performed in 5% CO2/1% O2 in a multi-gas incubator (ASTEC,
Fukuoka, Japan).
Plasmid Construction
The plasmid encoding PTD-ODD-HaloTag7 protein (POH)
was constructed by substituting coding sequences of procaspase-3
in the PTD3-ODD-procaspase-3 (POP33)[12] to HaloTag7
(Promega, Madison, WI, USA). The plasmid encoding POmH,
which contained the point substitution mutation (PRG)[19] at the
proline residue corresponding to HIF-1a P564 was prepared by
using the QuickChange XL site-directed mutagenesis kit (Strata-
gene, La Jolla, CA, USA). Final cDNA constructs were inserted
into the plasmid pGEX-6P-3 (GE Healthcare Bio-Science Corp.,
Piscataway, NJ, USA).
Preparation of fusion proteins
Fusion proteins were expressed in BL21-CodonPlus cells
(Stratagene, La Jolla, CA, USA) as GST-tagged proteins. The
GST-tagged proteins were a prepared essentially as previously
described [12], purified with a GST-column and digested with
precision protease (GE healthcare Bio-Science Corp.) to remove
GST-tag from the fusion proteins. The final products were
equilibrated in Mg
2+-/Ca
2+-free PBS (pH 8.0).
Isolation of PHD2-KD clones
The PHD2-KD cell lines were obtained by stable transfection of
a PHD2-specific shRNA plasmid into SUIT-2/HRE-Luc cells and
the KD1, KD2 and KD3 clones were selected by the indication of
high luciferase expression under normoxic conditions.
Figure 4. ODD function of POH probe in vitro and in vivo. (A) Time-dependent degradation of POH-I and POmH-I in HIF (-) cells. SUIT-2/HRE-Luc
cells cultured under normoxic conditions were co-cultured with POH-I or POmH-I for 1 h. The cells were cultured in fresh medium and the probes
remained in the cells was estimated by the measurement of fluorescent intensity of cell lysates at the represented time-points, shown by the relative
value (0 h=1). Degradation of POH and POmH protein was also detected by western blotting (lower panels). (B and C) Biodistribution of POH-I and
POmH-I in the whole body. Mice without xenografting were imaged at the indicated time after 2 nmol intravenous administration of POH-I or POmH-I
(B). Fluorescent intensity of the whole mouse was measured at the indicated time after administration of POH-I or POmH-I and relative fluorescent
intensities are shown (C). *P,0.01 (n=4). (D) In vivo imaging with POmH-I. Nude mice carrying SUIT-2/HRE-Luc xenografts in both forefeet were
injected with 2 nmol of POmH-I and images were taken at the indicated times. The right panel (HIF-1) shows bioluminescence images at 24 h. (E)
Fluorescence intensities of tumors and the muscle after POH-I (n=4) or POmH-I (n=6) administration were measured at the indicated time and
relative fluorescent intensities are shown. *P,0.01.
doi:10.1371/journal.pone.0015736.g004
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The HaloTag ligand-IR800 was provided by Promega Corpo-
ration (Madison, WI, USA). HaloTag Amine (O4) Ligands (1 mg,
2.87 mmol, Promega) in 100 ml of dimethyl formamide (DMF)
were mixed with Alexa Fluor 750 succinimidyl ester (1 mg,
,0.8 mmol, Invitrogen, Carlsbad, CA, USA) in 1 ml of 10 mM
boric acid (pH 8.5) in DMF. The reaction mixture was stirred for
12 h at room temperature in the dark. The reaction mixture was
applied to a SepPak C18 reverse-phase column (Waters, Milford,
MA, USA) and the HaloTag Ligands labeled with near-infrared
fluorescence substances (HL-N) were resolved in 100 ml of DMF.
POH protein (40 mmol/L) was mixed with 2 volumes of HL-N (80
nmol/15 ml) in 10 ml of PBS (pH 8.0) containing 100 mM Tris-
HCl (pH 8.0) and 3 M (NH4)2SO4 for 2 h. Then, the POH-N
probes were purified with a PD-10 gel filtration column (GE
Healthcare, Waukesha, WI, USA) and an Amicon-10 centrifuga-
tion column (Millipore, Milford, MA, USA). The purified POH-N
was finally resolved in PBS (pH 8.0). Fluorescence characteriza-
tions were confirmed by SDS-PAGE fluorescence imaging and the
labeling rate was calculated as described by the manufacturer. The
labeling rate was .0.7.
Preparation of the polyclonal anti-ODD antibody
The polyclonal anti-ODD antibody was provided by Oriental
Yeast Co., Ltd. The polypeptide QDTDLDLEMLAPYIPMD-
DDFQLRSFDQLSPLESSSAwasconjugatedtoKHLand injected
into two rabbits at 4-week intervals. The serum was harvested 8
weeks after the first immunization and purified with an affinity
column. The specificity of the purified antibody to PTD-ODD
fusion proteins was examined by western blotting and fluorescence
microscopic observation (Figure S6).
Western blotting
For analysis of cultured cells, SUIT-2/5HRE-Luc cells
(2.0610
5 cells/well) were seeded in a six-well plate. The cells
were pre-incubated under aerobic or hypoxic conditions with or
without 250 mMC o C l 2 for 5 h. Then, 50 mg of the probe was
added and incubated for 1 h under the same conditions as for
preincubation. The cells then were washed with medium,
incubated for 3 h, and lysed using 200 ml of Laemmli sample
buffer. The protein samples were electrophoresed on 12.5% (for
ODD, PHD2 and actin) or 10% (for HIF-1a)S D S - p o l y a c r y l -
amide gel and transferred to Hybond ECL membranes (GE
Healthcare). The POH-N probe, actin and HIF-1a were detected
with 10 mg/ml of a polyclonal anti-ODD antibody, 0.75 mg/ml
of a monoclonal anti-actin antibody (Sigma Life Science), and
0.25 mg/ml of a monoclonal anti-HIF-1a antibody (BD Biosci-
ences Pharmingen, San Diego, CA, USA), respectively. The
primary antibodies were then reacted with appropriate secondary
horseradish peroxidase-conjugated antibodies (GE Healthcare).
Signals were detected using the chemiluminescent ECL-PLUS
system (GE Healthcare).
Figure 5. Intratumoral localization of POH probe. (A) Immunohistochemical analyses of SUIT-2/HRE-Luc xenografts. Tumors were removed 6 h
after POH-I or POmH-I administration and examined for sever hypoxic regions (Pimo), HIF (+) cells (HIF-1a), probes (POH/POmH) and blood vessel
(CD31). Bars =100 mm. (B) Cellular localization of HIF-1a and POH. Tumors were excised 6 h after probe injection and examined for cell nuclei (DAPI)
and HIF-1a or POH. Bars =100 mm.
doi:10.1371/journal.pone.0015736.g005
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15736Figure 6. In vivo optical imaging of HIF-1 activity in an orthotopic pancreatic cancer model with POH probes. (A) In vivo imaging of
pancreatic cancer. Nude mice were orthotopically injected with SUIT-2/HRE-Luc cells and 11 days (upper panels) or 19 days (bottom panels) later the
mice were intraperitoneally injected with POH-I or POH-A and imaged at the indicated times after probe administration. Bioluminescence images
(HIF-1) of the mice 24 h after probe administration are shown in the right panels. (B and C) Ex vivo imaging of pancreatic cancer. The mice shown in
the upper and lower panels of (A) were analyzed by ex vivo imaging and shown in (B) and (C), respectively. Fluorescence (POH-I or POH-A) and
bioluminescence (HIF-1) images at 24 h are shown. Bar =10 mm (B) or 5 mm (C). (D) Three dimensional analysis of acquired fluorescent (POH-A) and
bioluminescent (HIF-1) images. A mouse with pancreatic cancer was injected with POH-A 10 days after orthotopic transplantation and were imaged
24 h after POH-A injection. (E) A mouse with pancreatic cancer was injected with POH-I 11 and 19 days after orthotopic transplantation. Fluorescence
(POH-I) and bioluminescence (HIF-1) images were taken 24 h after POH-I injection on the indicated days.
doi:10.1371/journal.pone.0015736.g006
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Samples were embedded in Tissue-Tek OCT compound
(Sakura Finetechnical, Tokyo, Japan) in dry ice/ethanol baths.
Cryosections (10 mm thick) were prepared using a cryostat (Leica
CM3050S, Leica Microsystems, Wetzlar, Germany) and fixed in
4% paraformaldehyde. Then sections were incubated with
blocking solution (1% BSA, Nacalai Tesque) for 30 min at room
temperature. The primary antibodies were incubated overnight at
4uC. TRITC-conjugated swine anti-rabbit (1/40 dilution in PBS,
Dako, Glostrup, Denmark) and Alexa Fluor 680-labeled goat anti-
rat (1/50 dilution in PBS, Invitrogen) secondary antibodies, as
appropriate, were used to fluorescently label the corresponding
primary antibodies. Cryosections (10 mm thick) were incubated for
1 h with FITC-conjugated Hypoxyprobe-1 primary antibody
supplied with the kit (Hypoxyprobe-1 Plus Kit, Chemicon
International). For DAPI staining, the sections were mounted in
Vectashield with DAPI (Vector Laboratories, Burlingame, CA,
USA). All photos were taken using a BZ-9000 microscope
(Keyence, Osaka, Japan).
Transplantation of subcutaneous and orthotopic
pancreatic cancer xenografts
For subcutaneous xenografts, SUIT-2/HRE-Luc cells suspend-
ed in PBS (1.0610
6 cells/20 ml) were mixed with an equal volume
of Geltrex (Invitrogen) and injected into both forelegs of 7-week-
old male nude mice. For the orthotopic pancreatic cancer model,
SUIT-2/HRE-Luc cells (2610
5 cells/50 ml) were mixed in an
equal volume of Geltrex (Invitrogen) and were injected into the
pancreas of 8-week-old male nude mice. Mice with subcutaneous
tumors of 5–15 mm in diameter were used for experiments.
In vivo and ex vivo bioluminescence imaging
For in vivo photon counting to assess bioluminescence, tumor-
bearing mice were intraperitoneally injected with 200 mlo fD -
luciferin solution (10 mg/ml in PBS, Promega) and placed in an
IVISH-Spectrum in vivo photon-counting device (Caliper Life
Sciences, Alameda, CA, USA). Bioluminescence images were
acquired at 20 min for subcutaneous xenografts and 13 min for
the pancreatic cancer model after the intraperitoneal injection of
D-luciferin. For ex vivo imaging, randomly selected mice were
sacrificed immediately after the in vivo imaging and biolumines-
cence images of the bodies and their organs were measured within
10 min after in vivo imaging. The following conditions were used
for image acquisition: exposure time =2 min (for in vivo) or 1 min
(for ex vivo), lamp level = high, binning = medium:8, field of view
=19 619 cm (for in vivo), 12.9612.9 cm (for ex vivo), and f/stop
=1. The bioluminescence was analyzed by Living Image 3.10
software (Caliper Life Sciences). Because the background biolu-
minescence of untreated nude mice (with D-luciferin injection) was
less than 4000 photon counts/s, we considered signals of .1610
4
photon counts/s as significant. The minimum and maximum
photons/s/cm
2/sr of each image are indicated in each figure by a
rainbow bar scale.
In vitro fluorescent imaging
SUIT-2/HRE-Luc, A549 lung adenocarcinoma, or HeLa
human cervical cancer cells (2610
5 cells/well) were seeded in a
six-well plate. The cells were pre-incubated under aerobic or
hypoxic conditions for 16 h with or without 250 mM CoCl2 for
5 h, followed by the addition of 500 nM of probe, and incubated
for 1 h. The cells were then washed with fresh medium, incubated
for indicated time in fresh medium, and suspended in 200 mlo f
radio-immunoprecipitation assay (RIPA) buffer. Fluorescent
imaging was performed for 150 ml of the suspensions in the 96-
well plate.
In vivo fluorescence imaging
Two nmol of POH-N, OH-I and POmH-I in 100 ml of PBS
(pH 8.0) were injected into tumor-bearing mice intravenously or
intraperitoneally. Fluorescence images were acquired at the
indicated times. All of the fluorescence images were acquired
with IVISH- Spectrum (Caliper Life Sciences) using the same
parameters for the excitation filter (710615 nm), emission filter
(780610 nm for POH-A; 800610 nm for POH-I, OH-I and
POmH-I) and exposure time =1 s, binning = medium (8), field
of view =19619 cm, f/stop=1.
Analysis of T/B ratio
Photon flux/sec in the same area (region of interest: ROI) of the
tumors and the muscle in the lower limbs were counted at the
indicated time after probe injection. Each photon flux/sec was
normalized by subtracting photon flux/sec in the corresponding
ROI of an untreated mouse. T/B was calculated by dividing the
normalized values in tumors by the ones in the muscle.
Ex vivo optical imaging
Randomly selected mice were sacrificed after the in vivo imaging
and organs were harvested. Fluorescence emissions from these
organs were measured with the IVIS Spectrum system using the
same parameters for the excitation filter (710615 nm), emission
filter (780610 nm for POH-A; 800610 nm for POH-I and OH-I
and POmH-I), and exposure time (1 s). In addition, biolumines-
cence images were acquired to assess HIF-1 activity in tumors with
a 1-min exposure time. The additional following conditions:
lamp Level = high, binning = medium (8), field of view =
12.9612.9 cm, f/stop=1 were used for image acquisition.
Three-dimensional fluorescence imaging
Surface topography and transillumination imaging system were
used to obtain information for constructing a three-dimensional
fluorescence image of 24 h after POH-A administration in an
orthotopic pancreatic cancer mouse and 6 h after POH-I
administration in a brain ischemic mouse. A series of fluorescence
images were taken at 17 different transillumination points around
the abdominal area for the pancreatic cancer model. The
following conditions: exposure time =1 s, binning = medium
(8), field of view =19619 cm, f/stop =1 and excitation
(710615 nm) and emission (780610 nm) filters were used for
image acquisition. For three-dimensional bioluminescence imag-
ing in the pancreatic cancer model, bioluminescence images were
acquired with three different wavelength (600610, 620610,
640610 nm) of bioluminescence filters. The following conditions
were used for image acquisition: exposure time =2 min, lamp
level = high, binning = medium (8), field of view =19619 cm
and f/stop =1.
Analysis of cell penetrating activity of PTD-ODD-EGFP
fusion proteins by fluorescence-activated cell sorter
Expression vector plasmids for the PTD fusion proteins were
constructed by inserting the cDNA fragments encoding PTD,
which was prepared by annealing the corresponding oligonucle-
otides, ODD and EGFP, which were prepared by PCR
amplification with the corresponding primers, into the plasmid
pGEX-6P-3. Recombinant proteins were prepared as previously
described [12], suspended in PBS at a final concentration of
50 mM and added to the culture medium of Suit-2 cells at the final
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30 min, trypsinized and suspended in 300 mL of icecold PBS. The
fluorescence intensity of the cells was determined by fluorescence-
activated cell sorting using CellQuest (Becton Dickinson).
Statistical analysis
Statistical analyses were carried out with a Student’s t test.
Values of P,0.05 were considered statistically significant.
Pearson’s correlation coefficient was also calculated for evaluation
of the correlation of data sets.
Supporting Information
Figure S1 The cell penetrating activity of PTD-ODD
fusion proteins. (A) Evaluation of PTD membrane permeabil-
ity. Left panel shows a representative FACS analysis of EGFP,
which did not penetrate the cell membrane and was used as a
negative control (NC) and nona-Lys-ODD-EGFP (K9OE). The
peaks corresponding to the fluorescence intensity (y) of PTD-
ODD-EGFP proteins were divided by the peak of fluorescence
intensity of EGFP (x) and are indicated on the graph as relative
fluorescence intensity (right panel). The experiments were done in
triplicate and repeated three times. Results are indicated as mean
6 SEM. P3OE: PTD3-ODD-EGFP, K9OE: 9K-ODD-EGFP,
R9OE: 9R-ODD-EGFP, TAT-OE: Tat-ODD-EGFP.
(TIF)
Figure S2 The specificity of POH-I probe to HIF (+) cells
in vitro. A549 (a human lung adenocarcinoma cell line) and
HeLa (a human cervical cancer cell line) cells cultured under
normoxic (N) or hypoxic (H) conditions or normoxic conditions in
the presence of 250 mM CoCl2 (Co) were treated with POH-I.
Fluorescent intensity of cell lysates of POH-I treated cells were
measured at an Ex/Em wavelength of 710 nm/800 nm. The
experiments were repeated three times and the results are
presented as mean 6 SEM. *P,0.05 vs. the normoxic condition.
Representative fluorescence images taken by IVIS are shown
below the graph.
(TIF)
Figure S3 Representative ex vivo florescent images of
organs 24 h after POH-I injection. Mice with subcutaneous
xenografts of SUIT-2/5HRE-Luc cells were injected intravenously
with 2 nmol of POH-I. Representative ex vivo images of organs at
24 h after POH-I injection are shown. 1-heart, 2-lung, 3-kidney,
4-liver, 5-muscle, 6-spleen, 7-stomach, 8-intestine.
(TIF)
Figure S4 In vivo optical imaging of orthotopic pancre-
atic cancer mice after intravenous injection with the
POH probe. Mice were injected with 1 nmol of POH-A via the
tail vein. The fluorescence images were taken at the indicated
times after POH-A injection. Bioluminescence imaging (HIF-1)
was taken 24 h after POH-A injection.
(TIF)
Figure S5 Representative ex vivo optical images of
organs from an orthotopic pancreatic cancer model
mouse without POH probe injection. Tumor-bearing mice
were sacrificed on day 19 after transplantation and bright field,
bioluminescence and fluorescence images were taken. Represen-
tative images for one mouse are shown. No autofluorescence was
observed with the imaging settings used (Ex/Em=710/780 nm).
The right panel indicates the labels of the organs depicted in the
other panels (1: muscle; 2: heart; 3: liver; 4: lung; 5: kidneys; 6:
bladder; 7: testis; 8: intestine; 9: stomach; 10: pancreatic tumor;
11: seminal vesicles; 12: testicle).
(TIF)
Figure S6 Evaluation of the polyclonal anti-ODD anti-
body for western blotting and immunohistochemical
analysis. (A) Western blotting was performed to evaluate the
specificity of the anti-ODD antibody. The indicated amounts of
purified POH protein and total cell lysate (Cell Lys) of SUIT-2/
HRE-Luc cells cultured under normoxic (N) or hypoxic (H)
conditions were electrophoresed on 12.5% (left) or 10% (right)
SDS-polyacrylamide gels and transferred to nitrocellulose mem-
branes. The resultant membranes were probed with 1 mg/ml of
the anti-ODD antibody (left) or 250 ng/ml of the monoclonal
anti-HIF-1a antibody (right). Cross-reactivity of the polyclonal
anti-ODD antibody to HIF-1a was negligible. The expected
molecular weights of HIF-1a and POH are indicated by
arrowheads. (B) Cellular immunostaining was examined for the
POH-treated and PBS-treated (control) SUIT-2/HRE-Luc cells
with anti-ODD antibody (green) and DAPI (blue). Cells (5610
4)
were cultured in a slide chamber and incubated with 10 mgo f
POH for 30 min, washed with PBS and fixed in 4% paraformal-
dehyde. The fixed cells were immunostained with 100 mg/ml of
anti-ODD antibody. DAPI staining was also performed according
to the manufacturer’s instructions. Bar =100 mm. Magnified
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